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No Evidence for Maternal–Fetal Microchimerism
in Infantile Hemangioma: A Molecular Genetic
Investigation
Kristianna M. Pittman1, H. Wolfgang Losken2, Mark E. Kleinman3, Jeffrey R. Marcus4, Francine Blei5,
Geoffrey C. Gurtner3 and Douglas A. Marchuk1
In this study, using the placental origin theory as a basis, we set out to explore whether hemangioma
endothelial cells (HEC) were maternal in origin. We rigorously addressed this hypothesis using several
molecular genetic techniques. Fluorescent in situ hybridization on surgical specimens of proliferating
hemangiomas (n¼ 8) demonstrated no XX-labeled HEC from resected tumors of male infants. This analysis was
followed by PCR genotyping of HEC (n¼ 11) using microsatellite markers where cellular components were
genotyped and compared to genomic DNA of corresponding mother–child pairs. In the seven informative
mother–child pairs, HEC matched the genotype of the child and not the maternal genotype. Concerned that
HEC represented a mixed population of cells, we subsequently enriched for cells using the placental-specific
endothelial cell (EC) marker, FcgRII. Three informative mother–child pairs exhibited only the genotype of the
child in our enriched cell population. Using sequence analysis, we identified an informative single nucleotide
polymorphism in an exon of the placental-EC-specific protein, GLUT1. When comparing GLUT1 complementary
DNA (cDNA) with mother–child DNA, the genotype of the cDNA matched the constitutional DNA of the child.
Our results indicate that hemangiomas are not microchimeric in origin. This study provides further insight into
the origin of a tumor whose pathogenesis remains elusive.
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INTRODUCTION
Hemangiomas are the most common tumor of infancy,
affecting a proportionately higher number of female infants
than male infants. Although classified as a benign tumor,
prevalence of the tumor, problems associated with its
aberrant growth, and the lack of uniformly effective treatment
options have warranted studies focusing on elucidating its
origin.
Fundamental studies by North et al. (2000, 2001)
identified the proteins, GLUT1, FcgRII, a2-laminin, and Lewis
Y antigen, as uniquely expressed on the endothelial cell (EC)
surface of infantile hemangiomas. These markers are also
mainly expressed at high levels on blood vessels in the
placenta. In studies performed subsequently, two other
reports have shown ECs constituting hemangiomas are clonal
in origin, suggesting clonal expansion from an endothelial
precursor cell (Boye et al., 2001; Walter et al., 2002). These
studies support the idea that the abnormal growth of
hemangiomas is due to an intrinsic property of the
endothelial component of the tumor. Collectively, these
studies have offered support to a theory that hemangioma
endothelial cells (HEC) acquire their placental phenotype
owing to clonal expansion of embolized precursor ECs
originating from placental vessels. Embolized placental ECs
could reach fetal tissues via right-to-left shunts in the fetal
circulation, where they would lodge in situ in the developing
fetus. This placental origin hypothesis is further upheld by the
observation that higher incidences of hemangiomas occur in
children whose mothers have undergone chorionic villus
sampling (Burton et al., 1995). The placental origin hypoth-
esis presents the possibility that the embolized ECs dislodged
into the fetal circulation may be from either the fetal or
maternal placental tissues.
The presence of a small number of maternal cells in fetal
tissues has been termed maternal microchimerism. The
clinical relevance of maternal microchimerism has been
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shown in several disease states. Artlett et al. (2000)
determined that maternal cells reside in the peripheral blood
and muscle tissue of children suffering from juvenile
idiopathic inflammatory myopathies. HLA genotyping re-
vealed that maternal microchimeric cells persist in peripheral
blood of immunocompetent individuals throughout their lives
(Maloney et al., 1999). In a pivotal study by Srivatsa et al.
(2003) it was determined that maternal cells can migrate out
of the fetal circulation into newborn tissues.
Because of the placental phenotype of HEC, maternal
microchimerism may be hypothesized to be involved in the
pathogenesis of hemangiomas. The purpose of this study was
to investigate maternal microchimerism in hemangiogenesis.
Proof that the tumor is maternally chimeric, would under-
line a potential mechanism for the aberrant growth of the
tumor.
RESULTS
Our intial approach to exploring maternal microchimerism in
hemangiomas was through fluorescent in situ hybridization
(FISH) analysis. We performed X/Y FISH staining on serial
sections of GLUT1þ proliferating hemangioma tissue from
eight resected tumors of male infants. Normal foreskin was
used as a control. No XX cells were identified within cells
lining the capillaries of the hemangioma. The percentage
of Yþ cells in HEC (Figure S1b, 67.375.3%) was not
statistically different from the foreskin controls (Figure S1a,
70.577.1%, Po0.05).
Our FISH results provided the foreground for a more
robust analysis of maternal microchimerism. We employed
microsatellite genotyping on fresh hemangioma tissue to
identify the origin (parent or child) of the EC component of
surgically resected tumors. Immediately after surgical resec-
tion, ECs from hemangiomas (n¼11) were magnetically
sorted using EC-specific cell surface marker CD105 (endoglin
sample 1–4) or CD31 (PECAM-1; samples 5–7). DNA was
extracted from the ECs, as well as the overlying skin of the
hemangioma, and peripheral blood leukocytes (PBL) of both
patient and mother. PCR genotyping was performed using
12 microsatellite markers, six mapping to the X chromo-
some and six mapping to several autosomes. Seven of the
11 hemangiomas were informative for at least two markers
(Table 1).
We sought evidence of maternal microchimerism, defined
as a complete match between hemangioma-derived EC
genotype and the mother’s genotype. As represented in
Figure 1a and 1b, for all seven informative mother–child
pairs, the CD105 and CD31-selected ECs matched the
constitutional genotype of the child also seen in hemangioma
stromal cells and PBLs from the child. They did not match the
Table 1. Genotype analysis of CD105 or CD31-selected hemangioma cells compared to hemangioma stromal cells,
genomic DNA of child, and genomic DNA of mother
Genotypes
Hemangioma P or I
Informative
markers Chr. locus Hemangioma EC
Hemangioma
stromal cells
Genomic DNA
of child
Genomic DNA
of mother
11 I GATA42G01 X AB AB AB BC
GATA0272 X BB BB BB AB
21 P ATCT057 X BC n.a. BC AB
GATA42G01 X BC n.a. BC AB
GATA027 X BC n.a. BC AB
31 P GATA10C11 X BB BB BB AB
GATA42G01 X BB BB BB AB
41 I GATA42G01 X BC BC BC AB
GATA32C12 7 AA AA AA AB
AGAT127 18 AB AB AB BC
GGAT2G03 3 BC BC BC AB
53 I AGAT127 18 AB AB AB AA
ATAC037 7 AA AA AA AB
63 I GGAA10C09N 14 AA AA AA AB
I ATAC037 7 BC BC BC AB
73 I GGAA10C09N 14 AB AB AB AA
ATAC0374 7 AC AC AC BC
EC, endothelial cell.
P or I, proliferating or involuting hemangioma.
1CD105-selected EC.
2Data presented in Figure 1a.
3CD31-selected EC.
4Data presented in Figure 1b.
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maternal genotype. As might have been expected, the
maternal DNA always shared one allele with child’s DNA
(refer to both Table 1 and Figure 1). These preliminary results
did not support maternal microchimerism.
Despite this result, we were concerned that the CD105
and CD31-selected ECs may have consisted of mixed
population of ECs from the hemangioma proper and other
ECs cell from surrounding vasculature. A mixed EC popula-
tion could obscure the evidence of microchimerism by
diluting the signal from the second maternal allele. We
attempted to improve our analyses by enriching for ECs
containing the placental expression phenotype. We at-
tempted this enrichment in two distinct ways. The first study
involved the use of FACS analysis to select for HEC that
expressed the placental phenotype. Cells were sorted and
selected for both CD31 and HEC marker FcgRII also known as
CD32. The structure of CD32 with a large extracellular
domain makes an ideal target for FACS analysis, enabling
efficient and specific detection of the ECs derived from the
tumor.
Total cell isolates from three hemangiomas (one prolifer-
ating and two involuting) were incubated with fluorescent-
tagged antibodies to CD32 and CD31. As expected, a greater
number of CD32/CD31-specific cells were sorted from a
proliferating hemangioma (Figure 2a) compared to involuting
(Figure 2b). PCR genotyping was performed using six
microsatellite markers from the X chromosome. We com-
pared the microsatellite repeat profile from DNA extracted
from CD32/CD31-positive cells, CD31-positive cells, PBLs
from the child, and PBLs from maternal blood (refer to
Figure 1c). All three mother–child pairs were informative
(Table 2). As previously observed, the hemangioma-derived
ECs matched the constitutional genotype of the child, as
found in the CD31 cells and PBLs from the child and not the
maternal genotype.
In a second approach, we used the expression of the
GLUT1 as a marker of the HEC. We reasoned that analysis of
GLUT1 messenger RNA (mRNA) would effectively identify
the origin of the HEC, provided that we could distinguish the
mother and child’s GLUT1 genotype. If maternal micro-
chimerism was present then the GLUT1 mRNA expressed
should resemble the maternal genotype at the mRNA
complementary DNA (cDNA) level. cDNA was generated
from unfractionated hemangioma tissue of six hemangiomas.
Genomic DNA was extracted from PBLs from mother–child
pairs. Each exon (nine total) from each sample was examined
for a heterozygous single nucleotide polymorphism (SNP). Of
six hemangiomas available for this analysis, only three were
informative. A region of variance was found in exon 4 for all
three pairs. The dbSNP rs11537641 (578C-T) was identified
and results in a synonymous change, C133C. In each of the
three cases, the informative allele expressed in the GLUT1
mRNA was similar to the patient’s genomic DNA and not
maternal genomic DNA (Figure 3).
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Figure 1. DNA from HECs do not exhibit the maternal genotype. (a, b).
Genotype results for two representative hemangioma samples. ECs were
magnetically sorted from hemangioma tissue using the EC-specific cell
surface markers, CD105 (endoglin), or CD31 (pan-EC surface marker).
Extracted DNA from sorted EC (lane 1) was genotyped using microsatellite
markers for X chromosome or autosomes and compared with the genotype of
DNA from overlying skin of the hemangioma (lane 2), and PBLs from the child
(lane 3) and mother (lane 4). (c) ECs were isolated through FACS analysis
using the hemangioma-specific EC marker CD32 and CD31. Extracted
DNA from CD32/CD31-specific ECs (lane 1) was genotyped as before
and compared with the genotype of DNA extracted from hemangioma
CD31 cells (lane 2), and PBLs from both child (lane 3) and mother
(lane 4).
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Figure 2. Proliferating hemangioma contains a greater number of CD32/
CD31 double-positive cells compared to involuting hemangioma. Heman-
gioma cells were double-labeled with antiphycoerythrin CD32 and anti-FITC
CD31. Cells were then sorted using flow cytometry. (a) A proliferating
hemangioma (6% of gated cells are CD32/CD31-positive). (b) An involuting
hemangioma (1% of gated cells are CD32/CD31-positive).
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DISCUSSION
The placental origin theory of hemangiogenesis maintains
that ECs from placental vessel could be dislodged from the
placenta, find residence in the developing fetus, and seed
formation of a hemangioma that would proliferate rapidly
after birth. This theory opens the possibility that the
embolized ECs dislodged into the fetal circulation are either
from fetal or maternal placental tissues. If HEC is derived
from the maternal side, hemangiogenesis would be another
medically-relevant example of maternal microchimerism.
We set out to investigate this hypothesis through molecular
genetic analysis of ECs derived from hemangiomas. We
began with FISH where no XX cells were identified in serial
sections of GLUT1þ proliferating hemangioma tissue from
eight resected tumors of male infants. Using PCR genotyping
of multiple microsatellite markers, we identified 10 heman-
giomas that were informative between the mother and her
child, that developed a hemangioma. Our initial results using
seven of these samples did not show evidence of the maternal
genotype in the hemangioma-derived ECs. Concerned that
our cell population was mixed, we attempted to enrich our
HEC population. An additional three hemangiomas were
subjected to more detailed analysis that amounted for
genotyping only the ECs with the placental expression
phenotype. In this instance, HEC were cell sorted both for
an EC and a placental cell-surface marker. Using an
alternative approach of expression genotyping, we identified
a sequence polymorphism in the coding region of GLUT1,
and then genotyped the transcript arising from the ECs. Both
analyses confirmed the lack of a maternal genotype in the
hemangioma-derived ECs.
The pathogenesis of hemangiomas has proven to be
difficult to ascertain. The major key to its pathogenesis has
been the strong correlation immunohistochemically between
the placental vasculature and the ECs of the hemangioma. To
date there has been at least seven markers identified that are
coexpressed on placental and hemangioma vessels; GLUT1,
merosin, Lewis Y antigen, Fcg-RII, type III iodothyronine,
indoleamine 2, 3 deoxygenase, and insulin-like growth factor 2
(Huang et al., 2000; North et al., 2000; North et al., 2001;
Ritter et al., 2002; Huang et al., 2003; Ritter et al., 2003).
Insulin-like growth factor 2 is expressed at high levels in
hemangiomas, however, this high expression was found not
be owing to a loss of imprinting (Yu et al., 2004). Barnes et al.
(2005) have recently strengthened the placental hypothesis
with their study molecularly profiling hemangiomas and
human placenta tissues. They identified three new genes,
tissue factor pathway inhibitor 2, 17b-hydroxysteroid deyh-
drogenase type 2 and g Drosophila homolog-like 1. It was
noted that 17b-hydroxysteroid dehydrogenase, g Drosophila
homolog-like 1 and insulin-like growth factor 2 are highly
expressed in proliferative hemangiomas as opposed to
involuting. They propose that the common genetic program
shared between the placental vasculature and the EC of the
hemangioma supports the placental origin theory and may
correspond to a tumor that functions analogously to the
placenta.
Table 2. Genotype analysis of CD32/CD31-selected hemangioma cells compared to hemangioma CD31-positive
cells, genomic DNA of child, and genomic DNA of mother
Genotypes
Hemangioma P or I
Informative
markers Chr. locus Hemangioma EC
Hemangioma
stromal cells
Genomic DNA
of child
Genomic DNA
of mother
8 I GATA10C111 X AA AA AA AB
AGAT104 X AA AA AA AB
GATA42G01 X BC BC BC AB
9 P GATA10C11 X BC BC BC AC
AGAT104 X CC CC CC AC
10 I GATA10C11 X AB AB AB BB
GATA42G01 X AB AB AB AA
P or I; proliferating, or involuting hemangioma; EC, endothelial cells.
1Presented in Figure 1c.
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Figure 3. GLUT1 transcript from hemangioma tissue does not exhibit the
maternal genotype. cDNA was generated from RNA extracted from
hemangioma tissue, reverse transcribed, and PCR amplified. The amplified
projects were subjected to DNA sequence analysis as a means to genotype the
expressed GLUT1 transcript, which is only expressed with the hemangioma
ECs. SNP rs1537461 in exon 4 is heterozygous in hemangiomas from this
mother–child pair. GLUT1 cDNA and genomic DNA of the child are
homozygous for the SNP-containing nucleotides CC at position 578.
The mother, however, is heterozygous containing nucleotides CT in this
same region.
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In conjunction with these findings, the results from our
current study have provided greater insight into the placental
phenotype of the tumor. We have determined that the
phenotype is not owing to any maternal component that is
represented in the tumor, and therefore the clonal expansion
of ECs in the tumor stems from a cell type derived from the
fetus. Other possible hypotheses, including mutation of ECs
residing in situ or stimulation of an EC precursor cell in the
fetus are also possible explanations to the phenotype.
MATERIALS AND METHODS
Samples
Blood samples and tissue specimens were obtained with informed
consent from a total of 34 hemangioma surgeries conducted at either
the University of North Carolina, Duke University, or New York
University, Departments of Plastic and Reconstructive Surgery.
The Institutional Review Boards of the participating Universities
approved the collection and use of these samples and experiments
according to the Declaration of Helsinki Principles. Participants gave
their written and informed consent. Hemangioma status, that is,
proliferating or involuting was determined under physician gui-
dance. Excluding archived tissue, 17 surgical specimens were
obtained from female patients and nine were obtained from male
patients (age range 4 months–3 years of age).
FISH
Hemangioma tissue from male infants and control foreskin were
formalin-fixed at the time of excision, and subsequently paraffin-
embedded (n¼ 8). Surgical specimens were confirmed to be
proliferating infantile hemangiomas by histopathology and
GLUT1þ immunofluorescence. FISH analysis was performed on
5mm serial sections of GLUT1þ proliferating hemangiomas and
control specimens. Slides were deparaffinized with xylene for
10 minutes 3, dried, and rinsed in 1 sodium chloride sodium
citrate buffer (Sigma, St Louis, MO). Sections were fixed in methanol/
acetic acid (3:1) for 30 seconds, dried, and then treated with
proteinase K, 10 mg/ml (Sigma), for 30 minutes at 371C. Slides were
incubated in 1% NP40 (Pierce, Rockford, IL) in phosphate-buffered
saline for 30 minutes at 371C. CEP X/Y DNA fluorescently labeled
probes (Vysis, Des Plaines, IL) were applied to the sections as per
manufacturer recommendations and then denatured at 801C.
Hybridization occurred overnight at 371C in a humidified chamber,
and we then removed non-hybridized probe with 50% formamide
and 2 sodium chloride sodium citrate buffer for 10 minutes at 651C
followed by 2 sodium chloride sodium citrate buffer and
2 sodium chloride sodium citrate buffer/0.5%, NP40 for 5 minutes
at 451C. Slides were counterstained with 4, 6-diamidino-2-phenyl-
indole, and mounted with Vectashield (Vector Laboratories,
Burlingame, CA). FISH signals for X/Y chromosomes were
enumerated using an Olympus microscope equipped with a triple-
pass filter.
Magnetic cell sorting
Immediately after surgery, hemangioma tissue was finely minced
under sterile conditions and placed in a 10 ml conical with a 1:5
dilution of Liberase Blendzyme 3 (Roche-Applied Science, Indiana-
polis, IN) in 1X phosphate-buffered saline. Conical was placed in
rocker at 371C for 10–20 minutes or until a slurry was formed. Cell
slurry was filtered using at first a 70 mm cell strainer and followed
with a 40 mm cell strainer (BD Biosciences, San Jose, CA). Filtered
slurry was then centrifuged for 10 minutes at 200 g. Cells were
rinsed and prepared for CD105 or CD31 sorting magnetically
according to company instructions (Miltenyi Biotec, Gladbach,
Germany).
PCR genotyping
Polymorphic tetranucleotide markers were chosen from the X
chromosome and autosomes based upon heterozygosity score
greater than 0.60 (Marshfield Clinic Research Foundation, Marsh-
field, WI). Genomic DNA was extracted from CD105 or CD31
magnetically sorted cells and PBL of mother and child using
Puregene DNA extraction kit (Gentra Systems, Minneapolis, MN).
Either the forward or reverse primer was incubated in a kinase
reaction containing T4 polynucleotide kinase, kinase buffer (Invitro-
gen Life Technologies, Carlsbad, CA) in an excess of gP32 ATP (ICN
Biomedicals, Costa Mesa, CA). Radiolabeled primer was then added
to PCR reaction mix containing 50 ng of DNA, PCR reaction mix,
Platinum Taq Polymerase (Invitrogen Life Technologies). Routine
PCR was performed with conditions varying with each tetranucleo-
tide marker. PCR products were run on a 4% non-denaturing
polyacrylamide gel. The gel was dried and exposed to Kodak
X-Omat LS film (Eastman Kodak, New Haven, CT).
FACS sorting
Cell sorting of HECs using CD32 and CD31 cell surface markers was
achieved using flow cytometry. A single cell suspension was
generated as described above for magnetic cell isolation. Cells were
incubated with both FITC-labeled mouse anti-human CD31 and
phycoerythrin-labeled mouse anti-human CD32 (BD Pharmingen,
San Diego, CA). Cells were stained on ice in the dark for 30 minutes.
Background fluorescent was controlled for using anti-mouse
CompBeads (BD Pharmingen).
GLUT1 SNP analysis
GLUT1 gene sequence was obtained through the UCSC genome
browser (http://genome.ucsc.edu, GenBank accession number NM
_006516). Heterozygous SNP detection for genomic DNA was
performed by designing primers for each of the nine exons around
their corresponding flanking intronic sequence. Each exon was
amplified by PCR using 100 ng of genomic DNA extracted from PBLs
of mother and child described above. For mRNA expression analysis,
primers for coding exons were designed across intronic sequences to
ensure purity of total RNA extracted (primers available upon
request). For mRNA expression analysis, unfractionated hemangio-
ma tissue was placed in Trizol (Invitrogen Gibco BRL, Carlsbad, CA)
immediately after surgery and homogenized using a Polytron
homogenizer. Total RNA was extracted and cDNA was amplified
using 1–5mg of total RNA combined in a tube with random
hexamers, oligo dTs, Monkey Moloney Leukemia Virus reverse
transcriptase and 5X First Strand buffer (Invitrogen Life Techno-
logies). PCR products for both genomic DNA and cDNA were
loaded and run on 1% Agarose (Amresco, St Louis, MO) using 0.5%
Tris-borate EDTA. Products were eluted from the gel by freezing and
then centrifuging at 18,000 g for 10 minutes. Exons were
sequenced using the ABI PRISM Big Dye terminator chemistry
(PE Biosystems, Foster City, CA).
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